CompletedPhase 4

Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium

108 participantsStarted 2015-10-16

Plain-language summary

The objective of this study was to evaluate the efficacy of topical 0.2% loteprednol etabonate, a 'soft steroid', compared with topical 0.1% dexamethasone, which is widely used in postoperative pterygium excision to prevent the recurrence of pterygium. If 0.2% loteprednol etabonate is non-inferior in efficacy compared with 0.1% dexamethasone, it may be used postoperatively in pterygium excision patients with the benefit of a low incidence of ocular hypertension or secondary glaucoma.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who had pterygium excision with amniotic membrane transplantation and who had impending recurrent pterygium stage 3 defined as fibrovascular tissue not invading the cornea Exclusion Criteria: * recurrent pterygium * received adjunctive treatment with beta radiation, mitomycin C or 5-fluorouracil * glaucoma or intraocular pressure \> 21 mmHg * history of 5-fluorouracil or chloramphenicol allergy

What they're measuring

rate of true recurrent pterygium

Timeframe: 6 months

Trial details

NCT IDNCT04075227

SponsorWannisa Suphachearabhan

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-03-02

View on ClinicalTrials.gov More Recurrent Pterygium of Eye trials